Table of Contents
AI is becoming impossible to ignore in discussions about the future of drug development, and AI precision medicine sits at the center of that conversation. New tools promise to improve everything from patient recruitment and trial design to biomarker discovery and treatment selection, with the expectation that AI will help run faster, more efficient and more successful clinical trials. But there is a danger that the field will focus too heavily on the technology itself and not enough on the information that underpins it.
The Hidden Limitations Behind AI Precision Medicine
For decades, clinical trials have been designed primarily to answer a specific question: is a treatment safe and effective? That objective remains essential, but advances in technology now give researchers an opportunity to learn far more from every study than in the past. This is the key piece that needs addressing before the field can maximize the opportunities of AI precision medicine in clinical trial practice.
Why Traditional Trial Frameworks Fall Short
Trials typically focus on collecting the information needed to meet regulatory endpoints. While entirely appropriate for demonstrating efficacy and safety, this approach can miss opportunities to generate a deeper understanding of disease biology. Valuable insights into underpinning mechanisms and how they relate to patient response to therapy are often left unexplored, limiting how far AI precision medicine can actually go.
Why AI Precision Medicine Depends on Better Biological Data
AI is exceptionally good at identifying patterns within large and complex datasets. However, it cannot uncover information that has never been collected. If the underlying data fails to capture the biological diversity of patients or the mechanisms driving treatment response, even the most sophisticated AI precision medicine algorithms will have limited value.
New Technologies Generating Richer Data
Fortunately, the ability to generate this critical, underpinning data has advanced dramatically in recent years. New technologies now allow researchers to examine tissues, cells and disease processes at an unprecedented level of detail, combining gene expression, protein activity, molecular pathways, cellular interactions and tissue architecture into a much richer, unbiased picture of disease biology. Patient-derived models and organoids can also help investigate how biological features influence treatment response.
How AI Precision Medicine Accelerates Data Interpretation
Graham Price, UCB’s Head of Global Clinical Development, noted that AI probably pulls the efficiency and speed lever when it comes to data interpretation. Collecting data from the internal and external world, medical writing, predicting patient response and modelling trial designs are all areas of work that take a long time, but once the data exists, AI can accelerate things considerably going forward.
Expanding Which Patients Can Be Treated
Price pointed to the potential for AI models to examine molecular structure and mechanisms of action, then begin selecting a spectrum of populations where a therapy might work, already increasing the number of indications and patient types treatable with one new medical entity under this evolving approach to AI precision medicine.
A New Vision for AI Precision Medicine Through the Smart Trials Hub
This thinking is reflected in initiatives such as the Smart Trials Hub at King’s College London, established to address two persistent challenges in clinical research: limited understanding of why patients respond differently to therapies, and the underrepresentation of diverse populations in clinical trials. The Hub brings together tissues, clinical information, advanced molecular profiling from diverse patient populations, and patient-derived models to build a deeper understanding of disease biology.
AI as a Tool, Not the Starting Point
Importantly, AI is part of this approach to AI precision medicine, but the starting point is the biological evidence that feeds the AI engine. Machine learning then helps integrate and interpret these complex datasets, revealing patterns that would otherwise remain hidden.
Rethinking the Purpose of Clinical Trials
These approaches create an opportunity to rethink the role of clinical trials themselves. Rather than viewing trials solely as a mechanism for testing drugs, researchers should increasingly see them as opportunities to learn about human biology, with every enrolled patient representing a chance to better understand disease mechanisms and why treatments work differently across populations.
Redefining What Success Looks Like
The next generation of trials must maintain a focus on outcomes while also gathering and generating as much knowledge as possible. Success should not be measured solely by whether a study reaches its endpoint, but also by how much researchers learn about disease biology and patient response along the way — a shift that will require close partnership between industry and academia to fully realize the promise of AI precision medicine.
